You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cancer immunotherapies targeting the PD-1 signaling pathway
|
|---|---|
| Published in |
Journal of Biomedical Science, April 2017
|
| DOI | 10.1186/s12929-017-0329-9 |
| Pubmed ID | |
| Authors |
Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo |
| Abstract |
Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 29% |
| India | 3 | 21% |
| Turkey | 1 | 7% |
| Mexico | 1 | 7% |
| Austria | 1 | 7% |
| United Kingdom | 1 | 7% |
| Unknown | 3 | 21% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 64% |
| Scientists | 3 | 21% |
| Practitioners (doctors, other healthcare professionals) | 2 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 697 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Iran, Islamic Republic of | 1 | <1% |
| Unknown | 696 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 118 | 17% |
| Student > Ph. D. Student | 89 | 13% |
| Researcher | 86 | 12% |
| Student > Master | 86 | 12% |
| Other | 45 | 6% |
| Other | 102 | 15% |
| Unknown | 171 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 149 | 21% |
| Medicine and Dentistry | 126 | 18% |
| Immunology and Microbiology | 67 | 10% |
| Agricultural and Biological Sciences | 53 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 34 | 5% |
| Other | 83 | 12% |
| Unknown | 185 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 72. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2022.
All research outputs
#601,650
of 25,605,018 outputs
Outputs from Journal of Biomedical Science
#25
of 1,108 outputs
Outputs of similar age
#12,378
of 324,428 outputs
Outputs of similar age from Journal of Biomedical Science
#1
of 14 outputs
Altmetric has tracked 25,605,018 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,108 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,428 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.